Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance

The classical natural history of chronic myeloid leukemia (CML) has been drastically modified by the introduction of tyrosine kinase inhibitor (TKI) therapies. TKI discontinuation is currently possible in patients in deep molecular responses, using strict recommendations of molecular follow-up due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Imeri, Jusuf, Desterke, Christophe, Marcoux, Paul, Chaker, Diana, Oudrhiri, Noufissa, Fund, Xavier, Faivre, Jamila, Bennaceur-Griscelli, Annelise, Turhan, Ali G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062417/
https://www.ncbi.nlm.nih.gov/pubmed/37007090
http://dx.doi.org/10.3389/fonc.2023.1117781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062417/
https://www.ncbi.nlm.nih.gov/pubmed/37007090
http://dx.doi.org/10.3389/fonc.2023.1117781

Ejemplares similares